Morningstar
•
Nov 02, 2026
Regeneron Pharmaceuticals, Inc.: Regeneron Pharmaceuticals Earnings: Outstanding Results Driven by Dupixent Collaboration Revenue
Summary
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Technical Assessment: Bullish in the Intermediate-Term
Nov 02, 2026
•
CVX, TEVA
Analyst Report: Sanofi
Nov 02, 2026
•
SNY
Analyst Report: AstraZeneca PLC
Nov 02, 2026
•
AZN
Analyst Report: AbbVie Inc.
Nov 02, 2026
•
ABBV
Analyst Report: Illumina, Inc.
Oct 30, 2026
•
ILMN
